| Code | CSB-E04763h-IS |
| Size | 96T,5×96T,10×96T |
| Price | Request a Quote |
| Trial Size |
24T ELISA Kit Trial Size (Only USD$150/ kit) * Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >> Interested in a trial size? Please leave a message below.
|
| Have Questions? | Leave a Message or Start an on-line Chat |
Intra-assay Precision (Precision within an assay): CV%<8% | ||||||
Three samples of known concentration were tested twenty times on one plate to assess. | ||||||
Inter-assay Precision (Precision between assays): CV%<10% | ||||||
Three samples of known concentration were tested in twenty assays to assess. | ||||||
To assess the linearity of the assay, samples were spiked with high concentrations of human VEGFR-2/Flk-1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | ||||||
| Sample | Serum(n=4) | ||||
1:1 | Average % | 93 | ||||
Range % | 89-98 | |||||
1:2 | Average % | 101 | ||||
Range % | 96-107 | |||||
1:4 | Average % | 90 | ||||
Range % | 86-96 | |||||
1:8 | Average % | 98 | ||||
Range % | 91-103 | |||||
The recovery of human VEGFR-2/Flk-1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | ||||||
Sample Type | Average % Recovery | Range | ||||
Serum (n=5) | 91 | 86-96 | ||||
EDTA plasma (n=4) | 99 | 90-108 | ||||
![]() | ||||||
ng/ml | OD1 | OD2 | Average | Corrected | ||
5 | 3.168 | 3.334 | 3.251 | 3.081 | ||
2.5 | 2.596 | 2.667 | 2.632 | 2.461 | ||
1.25 | 1.830 | 1.978 | 1.904 | 1.734 | ||
0.625 | 1.163 | 1.229 | 1.196 | 1.026 | ||
0.312 | 0.738 | 0.721 | 0.729 | 0.559 | ||
0.156 | 0.535 | 0.513 | 0.524 | 0.354 | ||
0.078 | 0.306 | 0.334 | 0.320 | 0.150 | ||
0 | 0.168 | 0.172 | 0.170 |
| ||
This ELISA kit provides quantitative measurement of soluble VEGFR-2/Flk-1 (sVEGFR-2) in human samples, supporting research into angiogenesis-driven cardiovascular pathology. Because circulating sVEGFR-2 levels shift in response to endothelial activation and anti-angiogenic therapy, researchers need an assay calibrated to capture both baseline and disease-modulated concentrations across translational sample types.
Detection Range: The 0.078–5 ng/mL range aligns with reported circulating sVEGFR-2 concentrations in human plasma, which typically fall between 5–12 ng/mL in healthy adults and can decrease significantly during anti-VEGF treatment or heart failure progression. Most serum and plasma samples will require a modest 2–5× dilution, while tissue homogenates from ischemic or tumor-adjacent myocardium can generally be assayed with minimal adjustment.
Sensitivity: At 0.039 ng/mL, the assay detects sVEGFR-2 in low-abundance contexts such as diluted plasma from patients on VEGF pathway inhibitors or conditioned media from endothelial cell cultures with suppressed receptor shedding.
Sample Compatibility: Validation across serum, plasma, and tissue homogenates enables paired analyses linking circulating sVEGFR-2 to local receptor expression in ischemic or infarcted myocardial tissue within the same study.
Assay Efficiency: The 1–5 hour protocol and 50–100 µL sample volume accommodate serial blood draws from longitudinal cardiovascular monitoring studies where repeated sampling limits available volume.
This kit is well-suited for studies of myocardial ischemia, anti-angiogenic cardiotoxicity, and peripheral artery disease biomarker discovery.
There are currently no reviews for this product.